{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:44:51Z","timestamp":1789231491266,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104306"],"award-info":[{"award-number":["82104306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Program of Hunan Province","award":["2022RC1229"],"award-info":[{"award-number":["2022RC1229"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11095-024-03705-2","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T22:01:22Z","timestamp":1714428082000},"page":"899-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Various Approaches to Estimate Transplacental Clearance of Vancomycin for Predicting Fetal Concentrations using a Maternal\u2013Fetal Physiologically Based Pharmacokinetic Model"],"prefix":"10.1007","volume":"41","author":[{"given":"Yunan","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-2676","authenticated-orcid":false,"given":"Feifan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"1","key":"3705_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajog.2021.02.032","volume":"225","author":"BD Wesley","year":"2021","unstructured":"Wesley BD, Sewell CA, Chang CY, Hatfield KP, Nguyen CP. Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration. Am J Obstet Gynecol. 2021;225(1):21\u201332.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3705_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ajog.2021.04.227","volume":"225","author":"Z Ren","year":"2021","unstructured":"Ren Z, Bremer AA, Pawlyk AC. Drug development research in pregnant and lactating women. Am J Obstet Gynecol. 2021;225(1):33\u201342.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"3705_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2174\/1381612825666190319102812","volume":"25","author":"N Bouazza","year":"2019","unstructured":"Bouazza N, Foissac F, Hirt D, Urien S, Benaboud S, Lui G, Treluyer JM. Methodological approaches to evaluate fetal drug exposure. Curr Pharm Des. 2019;25(5):496\u2013504.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"3705_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/clpt.2011.320","volume":"91","author":"SM Huang","year":"2012","unstructured":"Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther. 2012;91(3):542\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3705_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"M Jamei","year":"2009","unstructured":"Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of \u2018bottom-up\u2019 vs \u2018top-down\u2019 recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53\u201375.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"3705_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","volume":"51","author":"K Abduljalil","year":"2012","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365\u201396.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3705_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/cpt.1748","volume":"107","author":"JJM Freriksen","year":"2020","unstructured":"Freriksen JJM, Schalkwijk S, Colbers AP, Abduljalil K, Russel FGM, Burger DM, Greupink R. Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling. Clin Pharmacol Ther. 2020;107(6):1352\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3705_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40262-016-0457-5","volume":"56","author":"MM De Sousa","year":"2017","unstructured":"De Sousa MM, Lui G, Zheng Y, Pressiat C, Hirt D, Valade E, Bouazza N, Foissac F, Blanche S, Treluyer JM, Urien S, Benaboud S. A physiologically-based pharmacokinetic model to predict human fetal exposure for a drug metabolized by several CYP450 pathways. Clin Pharmacokinet. 2017;56(5):537\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3705_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1124\/dmd.116.073957","volume":"45","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs. Drug Metab Dispos. 2017;45(8):939\u201346.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3705_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bcp.12815","volume":"81","author":"MM De Sousa","year":"2016","unstructured":"De Sousa MM, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, Bouazza N, Foissac F, Blanche S, L\u00ea MP, Peytavin G, Treluyer JM, Urien S, Benaboud S. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81(4):646\u201357.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3705_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-017-0583-8","volume":"57","author":"S Schalkwijk","year":"2018","unstructured":"Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, Russel FGM. Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2018;57(6):705\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3705_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/jcph.1515","volume":"60","author":"XI Liu","year":"2020","unstructured":"Liu XI, Momper JD, Rakhmanina N, van den Anker JN, Green DJ, Burckart GJ, Best BM, Mirochnick M, Capparelli EV, Dallmann A. Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir. J Clin Pharmacol. 2020;60(2):240\u201355.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3705_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40262-021-01103-0","volume":"61","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Pansari A, Ning J, Jamei M. Prediction of maternal and fetal acyclovir, emtricitabine, lamivudine, and metformin concentrations during pregnancy using a physiologically based pharmacokinetic modeling approach. Clin Pharmacokinet. 2022;61(5):725\u201348.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3705_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.121.000711","volume":"50","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Ning J, Pansari A, Pan X, Jamei M. Prediction of maternal and fetoplacental concentrations of cefazolin, cefuroxime, and amoxicillin during pregnancy using bottom-up physiologically based pharmacokinetic models. Drug Metab Dispos. 2022;50(4):386\u2013400.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3705_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pro.3819","volume":"29","author":"PJ Stogios","year":"2020","unstructured":"Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020;29(3):654\u201369.","journal-title":"Protein Sci"},{"issue":"4","key":"3705_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/psp4.12279","volume":"7","author":"C Emoto","year":"2018","unstructured":"Emoto C, Johnson TN, McPhail BT, Vinks AA, Fukuda T. Using a vancomycin PBPK model in special populations to elucidate case-based clinical PK observations. CPT Pharmacometrics Syst Pharmacol. 2018;7(4):237\u201350.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"3705_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin RA, Bauer LA, Miller DD. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3705_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.32.1.92","volume":"32","author":"M Boeckh","year":"1988","unstructured":"Boeckh M, Lode H, Borner K, H\u00f6ffken G, Wagner J, Koeppe P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother. 1988;32(1):92\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3705_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/AAC.31.3.393","volume":"31","author":"DP Healy","year":"1987","unstructured":"Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987;31(3):393\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3705_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/j.1552-4604.1980.tb01696.x","volume":"20","author":"DJ Krogstad","year":"1980","unstructured":"Krogstad DJ, Moellering RC Jr, Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980;20(4):197\u2013201.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"3705_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/clpt.1984.260","volume":"36","author":"NR Cutler","year":"1984","unstructured":"Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984;36(6):803\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3705_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1128\/AAC.34.4.550","volume":"34","author":"DP Healy","year":"1990","unstructured":"Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and \u201cred man syndrome\u201d: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother. 1990;34(4):550\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3705_CR23","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1128\/AAC.00712-11","volume":"55","author":"TP Lodise","year":"2011","unstructured":"Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother. 2011;55(12):5507\u201311.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3705_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14767058.2017.1306049","volume":"31","author":"CV Towers","year":"2018","unstructured":"Towers CV, Weitz B. Transplacental passage of vancomycin. J Matern Fetal Neonatal Med. 2018;31(8):1021\u20134.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"4","key":"3705_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/0002-9378(89)90766-7","volume":"161","author":"MP Reyes","year":"1989","unstructured":"Reyes MP, Ostrea EM Jr, Cabinian AE, Schmitt C, Rintelmann W. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol. 1989;161(4):977\u201381.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"3705_CR26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/01.AOG.0000260388.78339.b6","volume":"109","author":"J Laiprasert","year":"2007","unstructured":"Laiprasert J, Klein K, Mueller BA, Pearlman MD. Transplacental passage of vancomycin in noninfected term pregnant women. Obstet Gynecol. 2007;109(5):1105\u201310.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"3705_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/bdd.2510130409","volume":"13","author":"WG Shin","year":"1992","unstructured":"Shin WG, Lee MG, Lee MH, Kim ND. Pharmacokinetics of drugs in blood. VII: unusual distribution and blood storage effect of vancomycin. Biopharm Drug Dispos. 1992;13(4):305\u201310.","journal-title":"Biopharm Drug Dispos"},{"key":"3705_CR28","unstructured":"US FDA. Vancomycin Injection label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050671s024lbl.pdf. Acessed on January 10, 2024."},{"issue":"1","key":"3705_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","volume":"51","author":"A Marsot","year":"2012","unstructured":"Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51(1):1\u201313.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3705_CR30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259\u201376.","journal-title":"J Pharm Sci"},{"issue":"4","key":"3705_CR31","doi-asserted-by":"publisher","first-page":"331.e331","DOI":"10.1016\/j.ajog.2012.06.064","volume":"207","author":"T Nanovskaya","year":"2012","unstructured":"Nanovskaya T, Patrikeeva S, Zhan Y, Fokina V, Hankins GD, Ahmed MS. Transplacental transfer of vancomycin and telavancin. Am J Obstet Gynecol. 2012;207(4):331.e331-336.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3705_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1124\/jpet.300.1.26","volume":"300","author":"T Nanovskaya","year":"2002","unstructured":"Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300(1):26\u201333.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"3705_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2174\/138920007782109733","volume":"8","author":"J Yang","year":"2007","unstructured":"Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 2007;8(7):676\u201384.","journal-title":"Curr Drug Metab"},{"issue":"8","key":"3705_CR34","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/jac\/dkr201","volume":"66","author":"JG Hurdle","year":"2011","unstructured":"Hurdle JG, Heathcott AE, Yang L, Yan B, Lee RE. Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. J Antimicrob Chemother. 2011;66(8):1773\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"35","key":"3705_CR35","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1039\/D1TB01430G","volume":"9","author":"J Ndayishimiye","year":"2021","unstructured":"Ndayishimiye J, Cao Y, Kumeria T, Blaskovich MAT, Falconer JR, Popat A. Engineering mesoporous silica nanoparticles towards oral delivery of vancomycin. J Mater Chem B. 2021;9(35):7145\u201366.","journal-title":"J Mater Chem B"},{"issue":"5","key":"3705_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bcp.12685","volume":"80","author":"MM De Sousa","year":"2015","unstructured":"De Sousa MM, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, Blanche S, Treluyer JM, Benaboud S. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015;80(5):1031\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3705_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40262-019-00799-5","volume":"59","author":"P Mian","year":"2020","unstructured":"Mian P, van den Anker JN, van Calsteren K, Annaert P, Tibboel D, Pfister M, Allegaert K, Dallmann A. Physiologically based pharmacokinetic modeling to characterize acetaminophen pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) formation in non-pregnant and pregnant women. Clin Pharmacokinet. 2020;59(1):97\u2013110.","journal-title":"Clin Pharmacokinet"},{"issue":"25","key":"3705_CR38","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1021\/jm9810102","volume":"41","author":"S Winiwarter","year":"1998","unstructured":"Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennern\u00e4s H, Karl\u00e9n A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem. 1998;41(25):4939\u201349.","journal-title":"J Med Chem."},{"issue":"10","key":"3705_CR39","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1023\/A:1020483911355","volume":"19","author":"D Sun","year":"2002","unstructured":"Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19(10):1400\u201316.","journal-title":"Pharm Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-024-03705-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:07:23Z","timestamp":1716487643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-024-03705-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1007\/s11095-024-03705-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"10 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}